Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda Discontinues Development of Prostate Cancer Vaccine GVAX
November 3, 2008
- BI to Enter Market for Antidiabetics with BI 1356: Dr Barner
November 3, 2008
- Banyu to Close Tsukuba Research Institute
November 3, 2008
- Bio Japan 2008
October 27, 2008
- BP Levels, Hypotensive Targets at Initiation of Treatment Dropping: CareNet Survey
October 27, 2008
- NEW PRODUCTS
October 27, 2008
- AZ Strengthens Its Biopharmaceuticals R&D Pipeline: Mr Brennan
October 27, 2008
- Kitasato Univ.-Harvard School of Public Health Symposium
October 27, 2008
- R&D NEWS IN BRIEF
October 27, 2008
- Sports Improve Symptoms of Schizophrenia
October 27, 2008
- Korosho to Ally with Authorities from Other Countries to Eliminate Drug Lag
October 27, 2008
- Merck Serono, Bristol-Myers to Copromote Erbitux with 300 MRs
October 27, 2008
- SJP Seminar Focuses on Pharmacovigilance
October 27, 2008
- Kowa Obtains Global License for DPP-4 Inhibitor from Sanwa Kagaku
October 27, 2008
- REGULATORY NEWS IN BRIEF
October 27, 2008
- Meiji Seika to Develop Biocodex's Stiripentol for SMEI
October 27, 2008
- Korosho Plans to Expand Range of OTC Drugs: Mr Kishida
October 27, 2008
- Ajinomoto Licenses MoviPrep from Norgine
October 27, 2008
- JACDS Supports Korosho's Draft Ordinance Regarding Online Sales of OTC Drugs
October 27, 2008
- Fuji Biomedix Applies for Civil Rehabilitation, Toho to Acquire Its Dispensing Pharmacy Div.
October 27, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…